Isocitrate Dehydrogenase (IDH) Inhibitors Global Market Report 2025
상품코드:1769630
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 175 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
이소구연산 탈수소효소(IDH) 억제제 시장 규모는 향후 수년간 비약적인 성장이 전망됩니다. 2029년에는 연간 평균 성장률(CAGR) 26.7%로 성장할 전망이며, 63억 4,000만 달러로 성장이 예측됩니다. 예측되는 성장은 유리한 상환정책, 혈액암 유병률 증가, 종양의사의 의식 고조, 정밀의료 채용 확대, 헬스케어 인프라 및 종양센터 확대 등에 기인할 것으로 보입니다. 예측 기간 중 예상되는 주요 동향으로는 게놈 분자 진단의 진전, 전략적 제휴 및 라이선싱 계약, 약물 전달 시스템의 혁신, 진단기술의 주요 발전, 병용 요법 개발 등을 들 수 있습니다.
급성 골수성 백혈병(AML)의 이환율 상승이 향후 수년간 이소구연산 탈수소효소(IDH) 억제제 시장의 성장을 이끌 것으로 예측됩니다. AML은 빠르게 진행되는 혈액 및 골수의 암으로 백혈구의 이상 증식을 특징으로 하며 정상적인 혈구 생성을 저해합니다. 이 AML 증례의 증가는 인구의 고령화에 기인하는 바가 큽니다. 고령자는 골수 기능 및 면역 반응의 노화와 관련된 변화로 인해 이 침공성 암을 개발하기 쉬워지기 때문입니다. IDH 억제제는 변이된 IDH 효소를 표적으로 하여 저해함으로써 정상적인 혈구의 발달을 회복시키고 백혈병의 진행을 지연시킴으로써 AML 치료에 중요한 역할을 하고 있습니다. 예를 들어 호주를 거점으로 하는 비영리단체 Leukaemia Foundation의 2023년 2월 보고서에 따르면 2022년부터 2035년 사이에 7,000명 이상의 소아, 6,000명 이상의 젊은 성인, 10만 8,000명 이상의 25세에서 65세의 성인이 혈액암, 주로 급성림프아구성백혈병(ALL), AML, 비호지킨림프종(NHL)으로 진단될 것으로 예상되고 있습니다. 그 결과 AML 빈도 증가가 IDH 억제제 시장을 크게 끌어올릴 것으로 예상되고 있습니다.
이소구연산 탈수소효소(IDH) 억제제 시장의 주요 기업은 임상적응의 확대, 시장 투입 기간의 단축, IDH 변이형 암의 치료에 있어서의 경쟁력 강화를 위해, 약사 승인 취득을 우선하고 있습니다. 보건 당국이 승인하는 약사 승인은 의약품의 안전성 및 유효성을 확인하는 것으로 상업적인 출시에 필수적인 것입니다. 예를 들어 2024년 8월 프랑스 제약회사 세르비에 라보라투아르는 IDH1 또는 IDH2 변이를 가진 성세포종이나 핍돌기교종을 포함한 Grade2의 IDH 변이 글리오마 환자를 대상으로 승인된 첫 표적치료제인 VORANIGO(보라시데닙) 정제의 FDA 승인을 취득했습니다. 제3상 INDIGO 시험에서 VORANIGO는 무진행 생존기간 중앙값이 27.7개월이었던 반면 위약은 11.1개월이었습니다. 경구제제는 인용성이 높고 간편한 치료 선택지를 제공해 기존 치료법이 제한된 환자에게 큰 진보입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 이소구연산 탈수소효소(IDH) 억제제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 : 성장률 분석
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 실적 : 규모 및 성장(2019-2024년)
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 이소구연산 탈수소효소(IDH) 억제제 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 : 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
IDH1 변이수 유사 악성 종양
IDH2 변이수 유사 악성 종양
기타 유형
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 : 분자 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단일클론항체
펩티드
소분자
기타 분자 유형
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
오랄
비경구
피하
주제
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 : 용도별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
FLT3 억제제
DH 억제제
헤지호그 경로 억제제
기타 용도
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 : IDH1 변이수 유사 악성 종양 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
급성 골수성 백혈병(AML)
신경 교종 및 신경 교모종
담관암
연골육종
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 : IDH2 변이수 유사 악성 종양 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
급성 골수성 백혈병(AML)
골수 이형성 증후군(MDS)
혈관면역 아구성 T세포 림프종(AITL)
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 : 기타 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
IDH 변이를 수반하는 고형 종양
IDH 변이를 수반하는 전이성 암
희소암에서의 실험적 사용 및 적응외 사용
제7장 지역별 및 국가별 분석
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 이소구연산 탈수소효소(IDH) 억제제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
이소구연산 탈수소효소(IDH) 억제제 시장 : 경쟁 구도
이소구연산 탈수소효소(IDH) 억제제 시장 : 기업 프로파일
Roche Holding AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co., Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bristol-Myers Squibb Company : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
GlaxoSmithKline plc : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Eli Lilly and Company
Daiichi Sankyo Company Limited
Les Laboratoires Servier
Evotec SE
HUTCHMED(China)Limited
Rigel Pharmaceuticals Inc.
CStone Pharmaceuticals
Forma Therapeutics Holdings Inc.
Philogen SpA
Kura Oncology, Inc.
Philogen SpA
Agios Pharmaceuticals Inc.
Adooq Bioscience LLC
Taiho Pharmaceutical Co. Ltd.
Celgene Corporation
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
이소구연산 탈수소효소(IDH) 억제제 시장(2029년) : 새로운 기회를 제공하는 국가
이소구연산 탈수소효소(IDH) 억제제 시장(2029년) : 새로운 기회를 제공하는 부문
이소구연산 탈수소효소(IDH) 억제제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Isocitrate dehydrogenase (IDH) Inhibitors are a category of targeted cancer treatments aimed at inhibiting the activity of mutated IDH1 and IDH2 enzymes. These enzymes play a role in cellular metabolism, and mutations in their genes can result in abnormal cell proliferation and cancer progression.
The primary types of isocitrate dehydrogenase (IDH) inhibitors include IDH1 mutant medullary malignant tumors, IDH2 mutant medullary malignant tumors, and others. An IDH1 mutant medullary malignant tumor is a cancer that begins in the central (medullary) part of a tissue or organ and involves a mutation in the IDH1 gene. These therapies encompass various molecular forms, such as monoclonal antibodies, peptides, small molecules, and others, and can be administered via oral, parenteral, subcutaneous, and topical routes. Applications include FLT3 inhibitors, DH inhibitors, hedgehog pathway inhibitors, and more.
The isocitrate dehydrogenase (IDH) inhibitors market research report is one of a series of new reports from The Business Research Company that provides isocitrate dehydrogenase (IDH) inhibitors market statistics, including isocitrate dehydrogenase (IDH) inhibitors industry global market size, regional shares, competitors with an isocitrate dehydrogenase (IDH) inhibitors market share, detailed isocitrate dehydrogenase (IDH) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the isocitrate dehydrogenase (IDH) inhibitors industry. This isocitrate dehydrogenase (IDH) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The isocitrate dehydrogenase (IDH) inhibitors market size has grown exponentially in recent years. It will grow from $1.94 billion in 2024 to $2.46 billion in 2025 at a compound annual growth rate (CAGR) of 27.0%. The growth during the historic period can be credited to the rising occurrence of hematologic cancers, advancements in genetic profiling within oncology, successful clinical outcomes of targeted therapies, the implementation of precision medicine initiatives, and increased healthcare expenditures in oncology.
The isocitrate dehydrogenase (IDH) inhibitors market size is expected to see exponential growth in the next few years. It will grow to $6.34 billion in 2029 at a compound annual growth rate (CAGR) of 26.7%. The projected growth can be attributed to favorable reimbursement policies, an increasing prevalence of blood cancers, heightened awareness among oncologists, greater adoption of precision medicine, and the expansion of healthcare infrastructure and oncology centers. Key trends anticipated during the forecast period include progress in genomic and molecular diagnostics, strategic collaborations and licensing agreements, innovations in drug delivery systems, enhancements in diagnostic technologies, and the development of combination therapies.
The rising incidence of acute myeloid leukemia (AML) is expected to drive the growth of the isocitrate dehydrogenase (IDH) inhibitors market in the coming years. AML is a rapidly progressing cancer of the blood and bone marrow marked by the abnormal proliferation of white blood cells, which disrupts normal blood cell production. This increase in AML cases is largely attributed to the aging population, as older individuals are more susceptible to developing this aggressive cancer due to age-related changes in bone marrow function and immune response. IDH inhibitors play a crucial role in treating AML by targeting and blocking mutated IDH enzymes, thereby restoring normal blood cell development and slowing the progression of leukemia. For example, according to a February 2023 report by the Leukaemia Foundation, an Australia-based non-profit organization, between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25-65 are expected to be diagnosed with blood cancers, predominantly acute lymphoblastic leukemia (ALL), AML, and non-Hodgkin lymphoma (NHL). As a result, the growing frequency of AML is anticipated to significantly boost the IDH inhibitors market.
Major companies in the isocitrate dehydrogenase (IDH) inhibitors market are prioritizing regulatory approvals to expand clinical indications, accelerate time-to-market, and strengthen their competitive positioning in the treatment of IDH-mutant cancers. Regulatory approvals, granted by health authorities, confirm a drug's safety and efficacy and are essential for commercial launch. For example, in August 2024, Servier Laboratoires, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets-the first targeted therapy approved for patients with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. In the Phase 3 INDIGO trial, VORANIGO demonstrated a median progression-free survival of 27.7 months compared to 11.1 months with placebo. The oral formulation offers a well-tolerated and convenient treatment option, representing a significant advancement for patients with limited existing therapies.
In October 2022, Novo Nordisk A/S, a Denmark-based pharmaceutical company, acquired Forma Therapeutics for $1.1 billion. The acquisition aims to strengthen Novo Nordisk's scientific capabilities and pipeline in hemoglobinopathies by expanding its portfolio to include treatments for sickle cell disease and other rare blood disorders. Forma Therapeutics, a US-based biopharmaceutical company, is known for developing innovative therapies for various cancers, including those targeting mutated isocitrate dehydrogenase (IDH).
Major players in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology, Inc., Philogen S.p.A., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC.
North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in isocitrate dehydrogenase (IDH) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the isocitrate dehydrogenase (IDH) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The isocitrate dehydrogenase (IDH) inhibitors market consists of sales of selective IDH1 inhibitors, selective IDH2 inhibitors, dual IDH1/IDH2 inhibitors, combination therapies, and delivery forms. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods, such as formulation development, packaging, and regulatory support.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Isocitrate Dehydrogenase (IDH) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on isocitrate dehydrogenase (idh) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for isocitrate dehydrogenase (idh) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The isocitrate dehydrogenase (idh) inhibitors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: IDH1 Mutant Medullary Malignant Tumor; IDH2 Mutant Medullary Malignant Tumor; Other Types
2) By Molecule Type: Monoclonal Antibodies; Peptides; Small Molecules; Other Molecule Types
3) By Route Of Administration: Oral; Parenteral; Subcutaneous; Topical
4) By Application: FLT3 Inhibitor; DH Inhibitor; Hedgehog Pathway Inhibitor; Other Applications
Subsegments:
1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML); Glioma Or Glioblastoma; Cholangiocarcinoma; Chondrosarcoma
3. Isocitrate Dehydrogenase (IDH) Inhibitors Market Trends And Strategies
4. Isocitrate Dehydrogenase (IDH) Inhibitors Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Isocitrate Dehydrogenase (IDH) Inhibitors Growth Analysis And Strategic Analysis Framework
5.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market Growth Rate Analysis
5.4. Global Isocitrate Dehydrogenase (IDH) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Isocitrate Dehydrogenase (IDH) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Isocitrate Dehydrogenase (IDH) Inhibitors Total Addressable Market (TAM)
6.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Other Types
6.2. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Peptides
Small Molecules
Other Molecule Types
6.3. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Subcutaneous
Topical
6.4. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
FLT3 Inhibitor
DH Inhibitor
Hedgehog Pathway Inhibitor
Other Applications
6.5. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH1 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Myeloid Leukemia (AML)
Glioma Or Glioblastoma
Cholangiocarcinoma
Chondrosarcoma
6.6. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of IDH2 Mutant Medullary Malignant Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Angioimmunoblastic T-cell Lymphoma (AITL)
6.7. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Solid Tumors with IDH Mutations
Metastatic Cancers With IDH Alterations
Experimental Or Off-label Uses In Rare Cancers
7. Isocitrate Dehydrogenase (IDH) Inhibitors Market Regional And Country Analysis
7.1. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Isocitrate Dehydrogenase (IDH) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Isocitrate Dehydrogenase (IDH) Inhibitors Market
9.1. China Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
9.2. China Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Isocitrate Dehydrogenase (IDH) Inhibitors Market
10.1. India Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market
11.1. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
11.2. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market
12.1. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market
13.1. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market
14.1. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
14.2. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market
15.1. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
15.2. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market
16.1. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.1. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Isocitrate Dehydrogenase (IDH) Inhibitors Market
18.1. France Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.1. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market
21.1. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
21.2. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market
22.1. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market
23.1. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
23.2. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market
24.1. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
24.2. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market
26.1. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
26.2. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market
27.1. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market
28.1. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
28.2. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market
29.1. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market Overview
29.2. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Molecule Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Isocitrate Dehydrogenase (IDH) Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Isocitrate Dehydrogenase (IDH) Inhibitors Market Competitive Landscape And Company Profiles
